Last reviewed · How we verify
[F-18]-Fludeoxyglucose
[F-18]-Fludeoxyglucose is a Radiopharmaceutical; PET imaging agent Small molecule drug developed by University of Saskatchewan. It is currently FDA-approved for Oncology: detection and staging of various cancers (lung, breast, colorectal, lymphoma, melanoma), Neurology: evaluation of dementia and neurodegenerative disorders, Cardiology: assessment of myocardial viability in coronary artery disease. Also known as: FDG, Fluorodeoxyglucose, F-18-FDG.
[F-18]-Fludeoxyglucose is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues, enabling visualization of glucose uptake via positron emission tomography (PET) imaging.
[F-18]-Fludeoxyglucose is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues, enabling visualization of glucose uptake via positron emission tomography (PET) imaging. Used for Oncology: detection and staging of various cancers (lung, breast, colorectal, lymphoma, melanoma), Neurology: evaluation of dementia and neurodegenerative disorders, Cardiology: assessment of myocardial viability in coronary artery disease.
At a glance
| Generic name | [F-18]-Fludeoxyglucose |
|---|---|
| Also known as | FDG, Fluorodeoxyglucose, F-18-FDG |
| Sponsor | University of Saskatchewan |
| Drug class | Radiopharmaceutical; PET imaging agent |
| Target | Glucose transporter (GLUT1); hexokinase |
| Modality | Small molecule |
| Therapeutic area | Oncology; Neurology; Cardiology |
| Phase | FDA-approved |
Mechanism of action
The drug consists of fluorodeoxyglucose (FDG), a glucose molecule with a fluorine-18 radioisotope attached. Cancer cells and other metabolically active tissues consume glucose at higher rates than normal tissue, causing FDG to preferentially accumulate in these areas. The fluorine-18 emits positrons that are detected by PET scanners, producing images that reveal areas of abnormal metabolism.
Approved indications
- Oncology: detection and staging of various cancers (lung, breast, colorectal, lymphoma, melanoma)
- Neurology: evaluation of dementia and neurodegenerative disorders
- Cardiology: assessment of myocardial viability in coronary artery disease
Common side effects
- Radiation exposure
- Hypoglycemia (rare, from glucose load)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [F-18]-Fludeoxyglucose CI brief — competitive landscape report
- [F-18]-Fludeoxyglucose updates RSS · CI watch RSS
- University of Saskatchewan portfolio CI
Frequently asked questions about [F-18]-Fludeoxyglucose
What is [F-18]-Fludeoxyglucose?
How does [F-18]-Fludeoxyglucose work?
What is [F-18]-Fludeoxyglucose used for?
Who makes [F-18]-Fludeoxyglucose?
Is [F-18]-Fludeoxyglucose also known as anything else?
What drug class is [F-18]-Fludeoxyglucose in?
What development phase is [F-18]-Fludeoxyglucose in?
What are the side effects of [F-18]-Fludeoxyglucose?
What does [F-18]-Fludeoxyglucose target?
Related
- Drug class: All Radiopharmaceutical; PET imaging agent drugs
- Target: All drugs targeting Glucose transporter (GLUT1); hexokinase
- Manufacturer: University of Saskatchewan — full pipeline
- Therapeutic area: All drugs in Oncology; Neurology; Cardiology
- Indication: Drugs for Oncology: detection and staging of various cancers (lung, breast, colorectal, lymphoma, melanoma)
- Indication: Drugs for Neurology: evaluation of dementia and neurodegenerative disorders
- Indication: Drugs for Cardiology: assessment of myocardial viability in coronary artery disease
- Also known as: FDG, Fluorodeoxyglucose, F-18-FDG
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing